Last reviewed · How we verify
trabodenoson 4.5% BID
Trabodenoson is a selective adenosine receptor agonist that increases the activity of the A1 receptor.
Trabodenoson is a selective adenosine receptor agonist that increases the activity of the A1 receptor. Used for Treatment of glaucoma.
At a glance
| Generic name | trabodenoson 4.5% BID |
|---|---|
| Also known as | INO-8875 |
| Sponsor | Inotek Pharmaceuticals Corporation |
| Drug class | Adenosine receptor agonist |
| Target | A1 adenosine receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
By activating the A1 receptor, trabodenoson reduces intraocular pressure by increasing the outflow of aqueous humor from the eye. This is thought to be beneficial for the treatment of glaucoma.
Approved indications
- Treatment of glaucoma
Common side effects
- Headache
- Eye pain
- Eye irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |